179 related articles for article (PubMed ID: 36606718)
41. Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).
Cahu X; Chevallier P; Clavert A; Suarez F; Michallet M; Vincent L; Vigouroux S; Blaise D; Mariette C; Bilger K; Robin M; Yakoub-Agha I; Peffault de Latour R; Mohty M
Bone Marrow Transplant; 2014 Jun; 49(6):756-60. PubMed ID: 24614840
[TBL] [Abstract][Full Text] [Related]
42. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
43. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
Kharfan-Dabaja MA; Al Malki MM; Deotare U; Raj RV; El-Jurdi N; Majhail N; Cherry MA; Bashir Q; Darrah J; Nishihori T; Sibai H; Hamadani M; de Lima M; Gerds AT; Selby G; Qazilbash MH; Forman SJ; Ayala E; Lipton JH; Hari PN; Muzzafar T; Zhang L; Olteanu H; Perkins J; Sokol L; Kumar A; Ahmed S
Br J Haematol; 2017 Dec; 179(5):781-789. PubMed ID: 28980314
[TBL] [Abstract][Full Text] [Related]
44. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
45. Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis.
Kharfan-Dabaja MA; Reljic T; Murthy HS; Ayala E; Kumar A
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):703-709.e1. PubMed ID: 30145196
[TBL] [Abstract][Full Text] [Related]
46. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.
Gilleece MH; Labopin M; Savani BN; Yakoub-Agha I; Socié G; Gedde-Dahl T; Blaise D; Byrne JL; Craddock C; Cornelissen JJ; Arcese W; Forcade E; Crawley C; Polge E; Mohty M; Nagler A
Leukemia; 2020 Jan; 34(1):87-99. PubMed ID: 31363160
[TBL] [Abstract][Full Text] [Related]
47. Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT.
Nabergoj M; Mauff K; Beelen D; Ganser A; Kröger N; Stölzel F; Finke J; Passweg J; Cornelissen J; Schub N; Veelken JH; Beguin Y; Wilson K; Zuckerman T; Hunault-Berger M; Lioure B; Porras RP; Turlure P; Kerre T; Koster L; Hayden PJ; Onida F; Scheid C; Chalandon Y; Robin M; Yakoub-Agha I
Bone Marrow Transplant; 2022 Jul; 57(7):1072-1078. PubMed ID: 35459878
[TBL] [Abstract][Full Text] [Related]
48. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics.
Hamadani M; Ngoya M; Sureda A; Bashir Q; Litovich CA; Finel H; Chen Y; Boumendil A; Zain J; Castagna L; Cashen AF; Blaise D; Shadman M; Pastano R; Khimani F; Arat M; Dietrich S; Schmitz N; Glass B; Kharfan-Dabaja MA; Corradini P; Sauter CS; Montoto S; Kwon M; Herrera AF; Dreger P
Blood Adv; 2022 Feb; 6(3):920-930. PubMed ID: 34861680
[TBL] [Abstract][Full Text] [Related]
49. Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival.
Ertz-Archambault N; Kosiorek H; Slack JL; Lonzo ML; Greipp PT; Khera N; Kelemen K
Biol Blood Marrow Transplant; 2017 May; 23(5):782-789. PubMed ID: 28189903
[TBL] [Abstract][Full Text] [Related]
50. Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT.
McLornan DP; Malpassuti V; Lippinkhof-Kozijn A; Potter V; Beelen D; Bunjes D; Sengeloev H; Radujkovic A; Passweg J; Chalandon Y; Kröger N; Wulf GG; Johansson JE; Ciceri F; Bornhäuser M; Holler E; Guffroy B; Martin S; Neubauer A; Gramatski M; Robin M; Iacobelli S; Hayden P; Hernández Boluda JC; Czerw T; Yakoub-Agha I
Br J Haematol; 2020 Aug; 190(3):437-441. PubMed ID: 32108327
[TBL] [Abstract][Full Text] [Related]
51. Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.
Savani M; Ahn KW; Chen Y; Ahmed S; Cashen AF; Shadman M; Modi D; Khimani F; Cutler CS; Zain J; Brammer JE; Rezvani AR; Fenske TS; Sauter CS; Kharfan-Dabaja MA; Herrera AF; Hamadani M
Br J Haematol; 2022 Apr; 197(2):212-222. PubMed ID: 35106754
[TBL] [Abstract][Full Text] [Related]
52. Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML.
Ustun C; Wiseman AC; Defor TE; Yohe S; Linden MA; Oran B; Burke M; Warlick E; Miller JS; Weisdorf D
Bone Marrow Transplant; 2013 Nov; 48(11):1415-20. PubMed ID: 23933764
[TBL] [Abstract][Full Text] [Related]
53. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.
Kharfan-Dabaja MA; Labopin M; Brissot E; Kroger N; Finke J; Ciceri F; Deconinck E; Blaise D; Chevallier P; Gramatzki M; Ganser A; Stelljes M; Edinger M; Savani B; Ruggeri A; Sanz J; Nagler A; Mohty M
Br J Haematol; 2021 May; 193(3):592-601. PubMed ID: 33838047
[TBL] [Abstract][Full Text] [Related]
54. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
[TBL] [Abstract][Full Text] [Related]
55. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.
Sengsayadeth S; Gatwood KS; Boumendil A; Labopin M; Finke J; Ganser A; Stelljes M; Ehninger G; Beelen D; Niederwieser D; Blaise D; Dreger P; Mufti G; Chevallier P; Mailhol A; Gilleece MH; Gorin N; Esteve J; Ciceri F; Baron F; Schmid C; Giebel S; Mohty M; Savani BN; Nagler A
Blood Adv; 2018 Aug; 2(16):2127-2135. PubMed ID: 30143527
[TBL] [Abstract][Full Text] [Related]
56. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
57. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
[TBL] [Abstract][Full Text] [Related]
58. Hematopoietic Cell Transplant-Composite Risk (HCT-CR): A Novel Predictor of Prognosis in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Yegin ZA; Özkurt ZN; Dikyar A; Kaynar LA; Karacaoğlu Ö; Yağcı M
Transplant Proc; 2021; 53(6):2013-2020. PubMed ID: 34246474
[TBL] [Abstract][Full Text] [Related]
59. Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Abou Dalle I; Labopin M; Kröger N; Schroeder T; Finke J; Stelljes M; Neubauer A; Blaise D; Yakoub-Agha I; Salmenniemi U; Forcade E; Itäla-Remes M; Dreger P; Bug G; Passweg J; Heuser M; Choi G; Brissot E; Giebel S; Nagler A; Ciceri F; Bazarbachi A; Mohty M
Bone Marrow Transplant; 2023 Jul; 58(7):784-790. PubMed ID: 37041215
[TBL] [Abstract][Full Text] [Related]
60. Quality of Life following Allogeneic Stem Cell Transplantation for Patients Age >60 Years with Acute Myelogenous Leukemia.
Wright R; Oremek M; Davies D; Kewley C; Singh A; Taitt N; Kempshall E; Wilson K; Ingram W
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1527-1533. PubMed ID: 32422252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
